Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesApr 24 14:48 ET
Express News | HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $19
Moomoo 24/7Apr 24 14:38 ET
Travere, CSL Win Conditional Nod for Kidney Disease Therapy in EU
Seeking AlphaApr 24 08:31 ET
Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization
Travere Therapeutics (TVTX) and CSL Vifor said Wednesday the European Commission granted conditional marketing authorization for Filspari as a treatment for adults with primary Immunoglobulin A Nephro
MT NewswiresApr 24 04:27 ET
Express News | Travere Therapeutics Inc - CSL Vifor Expects to Launch Filspari in First European Markets in Second Half of 2024.
Moomoo 24/7Apr 24 03:00 ET
Express News | CSL Vifor and Travere Therapeutics Announce European Commission Approves Filspari® (Sparsentan) for the Treatment of Iga Nephropathy
Moomoo 24/7Apr 24 03:00 ET
Express News | Reported Earlier, Travere Therapeutics And CCL Vifor Get European Commission Approval Of Sparsentan For The Treatment Of IgA Nephropathy
Moomoo 24/7Apr 19 11:41 ET
Travere Therapeutics, Inc. (NASDAQ:TVTX) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 3x Travere Therapeutics, Inc. (NASDAQ:TVTX) is definitely a stock worth checking out, seeing as almost half of all the Biotechs companies i
Simply Wall StApr 19 09:59 ET
FYBR, BCRX and SABR Are Among After Hour Movers
Seeking AlphaApr 18 16:56 ET
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
4 analysts have shared their evaluations of Travere Therapeutics (NASDAQ:TVTX) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table provides a quick
BenzingaApr 17 15:00 ET
Express News | Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $13 Price Target
Moomoo 24/7Apr 17 13:23 ET
As More Rare Disease Therapies Launch, Their Prices Are Rising
Seeking AlphaApr 16 12:22 ET
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present eight posters in classical homocystinuria (HCU) at Society for Inherited Metabolic Disorders (SIMD) in Charlotte, North Carolina from April 14-17, 2024, and Genetic Metabolic Dieticians International (GMDI) in Charlotte, North Carolina from April 17-20, 2024.
GlobeNewswireApr 4 16:30 ET
Express News | Travere Therapeutics To Present Abstracts On FILSPARI In IgA Nephropathy At World Congress Of Nephrology And American Nephrology Nurses Association
Moomoo 24/7Apr 3 16:46 ET
Express News | Guggenheim Downgrades Travere Therapeutics to Neutral
Moomoo 24/7Mar 27 06:49 ET
Further Weakness as Travere Therapeutics (NASDAQ:TVTX) Drops 14% This Week, Taking Three-year Losses to 72%
Every investor on earth makes bad calls sometimes. But you have a problem if you face massive losses more than once in a while. So take a moment to sympathize with the long term shareholders of Trav
Simply Wall StMar 15 09:42 ET
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants
GlobeNewswireMar 13 17:00 ET
Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights
Travere Therapeutics (NASDAQ:TVTX) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.In the table below, you'll find a summary
BenzingaMar 13 10:00 ET
Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 13 09:55 ET
Express News | HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Maintains $17 Price Target
Moomoo 24/7Mar 13 09:45 ET
No Data
No Data